Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TOMM22 divergent transcript (TOMM22-DT, also known as lnc408) is a long non-coding RNA (lncRNA) gene not translated into protein. It is functionally implicated in the regulation of gene expression through interactions with macromolecules such as DNA, proteins, and other RNAs. TOMM22-DT (lnc408) has been identified as an inducer of epithelial-mesenchymal transformation and promotes breast cancer cell invasion and metastasis, likely by regulating cytoskeletal stability[1][3][7]. Diseases associated with TOMM22 divergent transcript include breast cancer. As a lncRNA, it is not itself a receptor, enzyme, transporter, or classical therapeutic target, but it may influence cancer progression through its regulatory roles in cellular processes[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TOMM22 divergent transcript (TOMM22-DT).